CureVac to lay off workers after licensing vaccines to GSK for up to $1.5B



CureVac NV, a German biopharma company with its U.S. headquarters in Boston, is restructuring after signing a licensing deal with GSK plc.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *